Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Lunch and Poster Display session

283P - Navigating sexuality and hormone therapy in early luminal breast cancer

Date

16 May 2024

Session

Lunch and Poster Display session

Presenters

Tiago Cabral

Citation

Annals of Oncology (2024) 9 (suppl_4): 1-12. 10.1016/esmoop/esmoop103324

Authors

T.A.D. Cabral1, V. Duarte Branco1, M. Lagarto1, M. Dorey1, M.M. Baleiras1, P. Cavaco2, J.R. Pereira1, S.L. Martins3, H. Miranda1, A. Martins1

Author affiliations

  • 1 Centro Hospitalar de Lisboa Ocidental E.P.E. (CHLO)-Hospital São Francisco Xavier (HSFX), Lisbon/PT
  • 2 Hospital S. Francisco Xavier, Restelo/PT
  • 3 HSM - Hospital Santa Maria - Centro Hospitalar Universitario de Lisboa Norte E.P.E., Lisbon/PT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 283P

Background

Breast Cancer (BC) advancements improved survival, but pose challenges in managing AEs, particularly sexual dysfunction in HT. This study focuses on HT-related sexual distress, emphasizing the need for support services.

Methods

Survey of pts with eBC undergoing adjuvant HT via EORTC SHQ-22 and FSDS-R.

Results

126 female pts with luminal eBC, median age of 55 years (min-max 33-81), 97.6% Caucasian. Median time of adjuvant HT was 29.5mo (min-max 3-132). 11.11% were under OFS. 42% pts were under tamoxifen (TAM), 29% Letrozole (LET), 15.8% Anastrozole (ANA) and 12% Exemestane (EXE). Median age in the TAM group was 51y, LET 63y; ANA 55y and EXE 48y. Median time of HT in the TAM group was 30mo; LET 22mo (; ANA 40mo and EXE 34.5mo. Any grade AE reported were: 57.9% hot flashes; 54.6% loss of sexual desire; 46.0% vaginal dryness; 42.3% mood swings; 40.5% irritability; 34.9% feeling bloated and 18.1% painful sex. In the TAM group, most comon AE: hot flashes (66.0%) and loss of sexual desire (60.4%); with LET: arthralgias (75.68%) and loss of sexual desire (45.9%); with ANA: arthralgias (85%), hot flashes (65.0%) and loss of sexual desire (55.1%); with EXE: arthralgias (100%), hot flashes (81.3%) and feeling “bloated” (68.8%). Regarding pts amorous relations 3, 2% separated after the diagnosis, 1.6% after initiating HT. During HT 4.8% changed partner and 23.8% remained single. About EORTC SHQ-22, 34.2% regard sexual life as "very much" important, 23.8% "quite a bit". 45.3% under TAM and 35.0% under ANA consider it very importante. 32.4% under LET regard sexual life as just “a little” important. Overall, 31.8% declared having significant loss of libido, 32.4% under LET and 50.0% under ANA. When asked about sexual satisfaction, 35.7% responded “not at all” (51.4% in the LET group). 27.8% regard “very much” and 19.1% “quite a bit” the impact of HT in their sexual life. FSDS-R median overall value was of 6.5 points (SD 14.4). Median value per group: TAM 7.0(SD 13.3), LET 2.0 (SD 15.8) and ANA of 5.0 (SD of 11.5). The highest median value was seen in the EXE group (15.0, SD 16.3).

Conclusions

Our study shows the strong link between sexual dysfunction and HT in Luminal eBC. This AEs emphasize the need for tailored support, personalized approaches and integrated sexual counseling, improving patients QoL and outcomes.

Legal entity responsible for the study

T. P. Cabral.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.